-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson plans to buy eye disease biotech company Ollin Biosciences for up to $3.4 billion. Under the agreement, Johnson & Johnson may pay Ollin supporters $2.2 billion in upfront cash, as well as another $1.2 billion in potential milestone payments.
Share
Listen to the news
Johnson & Johnson plans to buy eye disease biotech company Ollin Biosciences for up to $3.4 billion. Under the agreement, Johnson & Johnson may pay Ollin supporters $2.2 billion in upfront cash, as well as another $1.2 billion in potential milestone payments.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending